ketamine has been researched along with Behavior Disorders in 63 studies
Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.
ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This article examines the advantages and applications of INDD in neuropsychiatry; provides examples of test, experimental, and approved INDD treatments; and focuses especially on the potential of intranasal ketamine for the acute and maintenance therapy of refractory depression." | 8.91 | Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression. ( Andrade, C, 2015) |
| " Considering the lack of understanding concerning the pathophysiology of schizophrenia, the present study hypothesized that omega 3 prevents the onset of symptoms similar to schizophrenia in young Wistar rats submitted to ketamine treatment." | 7.80 | Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia. ( Binatti, AR; Budni, J; Chipindo, HL; da Rosa Silveira, F; de Oliveira, MB; Gama, CS; Heylmann, AS; Maravai, SG; Mastella, GA; Panizzutti, B; Quevedo, J; Schuck, PF; Steckert, AV; Volpato, AM; Wessler, PG; Zugno, AI, 2014) |
| "Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with demonstrated antidepressant effects in the adult population, however, the efficacy and safety of ketamine for the treatment of pediatric depression remains poorly understood." | 6.82 | Ketamine use in pediatric depression: A systematic review. ( Cao, B; Ceban, F; Chisamore, N; Danayan, K; Ho, RC; McIntyre, RS; Meshkat, S; Rhee, TG; Rosenblat, JD; Vincenzo, JDD, 2022) |
| " This article examines the advantages and applications of INDD in neuropsychiatry; provides examples of test, experimental, and approved INDD treatments; and focuses especially on the potential of intranasal ketamine for the acute and maintenance therapy of refractory depression." | 4.91 | Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression. ( Andrade, C, 2015) |
| " Considering the lack of understanding concerning the pathophysiology of schizophrenia, the present study hypothesized that omega 3 prevents the onset of symptoms similar to schizophrenia in young Wistar rats submitted to ketamine treatment." | 3.80 | Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia. ( Binatti, AR; Budni, J; Chipindo, HL; da Rosa Silveira, F; de Oliveira, MB; Gama, CS; Heylmann, AS; Maravai, SG; Mastella, GA; Panizzutti, B; Quevedo, J; Schuck, PF; Steckert, AV; Volpato, AM; Wessler, PG; Zugno, AI, 2014) |
| "Limited published data exists that collates serious adverse outcomes involving ketamine as a psychiatric intervention." | 3.54 | A systematic review of the incidence of medical serious adverse events in sub-anesthetic ketamine treatment of psychiatric disorders. ( Frizzell, W; Gerrish, W; Hovda, N; Shackelford, R, 2024) |
| "Ketamine has shown effect for the treatment of resistant depression." | 3.01 | ( Ibrahim, IB; Straszek, SPV; Videbech, P, 2023) |
| "Ketamine is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist with demonstrated antidepressant effects in the adult population, however, the efficacy and safety of ketamine for the treatment of pediatric depression remains poorly understood." | 2.82 | Ketamine use in pediatric depression: A systematic review. ( Cao, B; Ceban, F; Chisamore, N; Danayan, K; Ho, RC; McIntyre, RS; Meshkat, S; Rhee, TG; Rosenblat, JD; Vincenzo, JDD, 2022) |
| "Esketamine was recently licensed by the US Food and Drug Administration (FDA) and European Drug Agency (EDA) for use in treatment resistant depression (TRD), and further research indicates ketamine as a possible treatment in other mental health conditions." | 2.66 | Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review. ( Borissova, A; Curran, HV; Grabski, M; Marsh, B; Morgan, CJA, 2020) |
| "Ketamine has been available for approximately 50 years as an anesthetic agent." | 2.53 | Has psychiatry tamed the "ketamine tiger?" Considerations on its use for depression and anxiety. ( Rasmussen, KG, 2016) |
| "Ketamine is a dissociative anesthetic and substance of abuse." | 2.50 | Ketamine: an update on its abuse. ( Anderson, PD; Bokor, G, 2014) |
| "Ketamine is a phencyclidine derivative acting primarily as a noncompetitive antagonist of N-methyl-D-aspartate (NMDA) excitatory glutamate receptors." | 2.45 | [Advances in research of ketamine addiction mechanism]. ( Bian, SZ; Gu, ZL; Jiang, XG; Liu, WL; Qin, ZH, 2009) |
| " Ten adverse mental status events were documented in nine subjects/infusions that were deemed related to ketamine administration (2% of subjects, 1." | 2.44 | Psychiatric safety of ketamine in psychopharmacology research. ( Cho, HS; Cramer, JA; D'Souza, DC; Genovese, A; Karper, LP; Krystal, JH; O'Donnell, E; Perry, EB; Petrakis, IL, 2007) |
| "Ketamine is a noncompetitive NMDA receptor antagonist and comes into being a new problem of drug abuse." | 2.44 | [A reviewing for abusing of ketamine]. ( Bian, SZ; Yang, J, 2007) |
| "Ketamine has received increasing attention in recent years for pre-hospital sedation of behaviourally disturbed patients, predominantly with psychiatric illness." | 1.56 | Impact of a ketamine sedation protocol on intubation rates and undesirable outcomes in the transport of patients with acute behavioural disturbance. ( Johnson, R; Shahtahmasebi, R; Shahtahmasebi, S, 2020) |
| "Oral ketamine is an effective premedication for major ambulatory surgery and does not increase the incidence of side effects." | 1.36 | [Oral ketamine-midazolam premedication of uncooperative patients in major outpatient surgery]. ( Cano, G; Caparros, P; Cortiñas, M; Ibarra, M; Martínez, L; Oya, B, 2010) |
| " Addictive/dependent patterns of behaviour were also a concern: the majority of frequent users reported using the drug without stopping until supplies ran out and the mean increase in dosage in this group was six-fold from initiation to current use." | 1.35 | Journey through the K-hole: phenomenological aspects of ketamine use. ( Curran, HV; Kamboj, SK; Morgan, CJ; Muetzelfeldt, L; Rees, H; Taylor, J, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.76) | 18.7374 |
| 1990's | 2 (3.17) | 18.2507 |
| 2000's | 11 (17.46) | 29.6817 |
| 2010's | 27 (42.86) | 24.3611 |
| 2020's | 20 (31.75) | 2.80 |
| Authors | Studies |
|---|---|
| Dutton, M | 2 |
| Can, AT | 2 |
| Beaudequin, D | 1 |
| Jensen, E | 1 |
| Jones, M | 1 |
| Gallay, CC | 1 |
| Schwenn, PE | 1 |
| Scherman, JK | 1 |
| Yang, C | 1 |
| Forsyth, G | 1 |
| Lagopoulos, J | 2 |
| Hermens, DF | 2 |
| Giacobbe, P | 1 |
| Burhan, AM | 1 |
| Waxman, R | 1 |
| Ng, E | 1 |
| Miller, AH | 1 |
| Raison, CL | 1 |
| Young, AH | 1 |
| Ibrahim, IB | 1 |
| Videbech, P | 1 |
| Straszek, SPV | 1 |
| Meshkat, S | 1 |
| Rosenblat, JD | 1 |
| Ho, RC | 1 |
| Rhee, TG | 1 |
| Cao, B | 1 |
| Ceban, F | 1 |
| Danayan, K | 1 |
| Chisamore, N | 1 |
| Vincenzo, JDD | 1 |
| McIntyre, RS | 1 |
| Hovda, N | 1 |
| Gerrish, W | 1 |
| Frizzell, W | 1 |
| Shackelford, R | 1 |
| Wojtas, A | 1 |
| Cottone, JG | 1 |
| Nutt, D | 1 |
| Belenichev, I | 1 |
| Burlaka, B | 1 |
| Puzyrenko, A | 1 |
| Ryzhenko, O | 1 |
| Kurochkin, M | 1 |
| Yusuf, J | 1 |
| Corne, R | 1 |
| Mongeau, R | 1 |
| Grabski, M | 1 |
| Borissova, A | 1 |
| Marsh, B | 1 |
| Morgan, CJA | 1 |
| Curran, HV | 2 |
| Akinosoglou, K | 1 |
| Gogos, A | 1 |
| Papageorgiou, C | 1 |
| Angelopoulos, E | 1 |
| Gogos, C | 1 |
| De Gregorio, D | 1 |
| Aguilar-Valles, A | 1 |
| Preller, KH | 1 |
| Heifets, BD | 2 |
| Hibicke, M | 1 |
| Mitchell, J | 1 |
| Gobbi, G | 1 |
| Passie, T | 1 |
| Adams, HA | 1 |
| Logemann, F | 1 |
| Brandt, SD | 1 |
| Wiese, B | 1 |
| Karst, M | 1 |
| Davis-Reyes, BD | 1 |
| Smith, AE | 1 |
| Xu, J | 1 |
| Cunningham, KA | 1 |
| Zhou, J | 1 |
| Anastasio, NC | 1 |
| Włodarczyk, A | 1 |
| Cubała, WJ | 1 |
| Gąsior, M | 1 |
| Muthukumaraswamy, SD | 1 |
| Forsyth, A | 1 |
| Lumley, T | 1 |
| Davey, CG | 1 |
| Kadriu, B | 1 |
| Musazzi, L | 1 |
| Johnston, JN | 1 |
| Kalynchuk, LE | 1 |
| Caruncho, HJ | 1 |
| Popoli, M | 1 |
| Zarate, CA | 1 |
| Parsch, CS | 1 |
| Boonstra, A | 1 |
| Teubner, D | 1 |
| Emmerton, W | 1 |
| McKenny, B | 1 |
| Ellis, DY | 1 |
| Nazarian, DJ | 1 |
| Broder, JS | 1 |
| Thiessen, MEW | 1 |
| Wilson, MP | 1 |
| Zun, LS | 1 |
| Brown, MD | 1 |
| Phillips, AG | 1 |
| Geyer, MA | 1 |
| Robbins, TW | 1 |
| Thalman, C | 1 |
| Horta, G | 1 |
| Qiao, L | 1 |
| Endle, H | 1 |
| Tegeder, I | 1 |
| Cheng, H | 1 |
| Laube, G | 1 |
| Sigurdsson, T | 1 |
| Hauser, MJ | 1 |
| Tenzer, S | 1 |
| Distler, U | 1 |
| Aoki, J | 1 |
| Morris, AJ | 1 |
| Geisslinger, G | 1 |
| Röper, J | 1 |
| Kirischuk, S | 1 |
| Luhmann, HJ | 1 |
| Radyushkin, K | 1 |
| Nitsch, R | 1 |
| Vogt, J | 1 |
| Kozono, N | 1 |
| Honda, S | 1 |
| Tada, M | 1 |
| Kirihara, K | 1 |
| Zhao, Z | 1 |
| Jinde, S | 1 |
| Uka, T | 1 |
| Yamada, H | 1 |
| Matsumoto, M | 1 |
| Kasai, K | 1 |
| Mihara, T | 1 |
| Malenka, RC | 1 |
| Shahtahmasebi, R | 1 |
| Johnson, R | 1 |
| Shahtahmasebi, S | 1 |
| Carhart-Harris, RL | 1 |
| Brugger, S | 1 |
| Nutt, DJ | 1 |
| Stone, JM | 1 |
| Arnold, C | 1 |
| Zugno, AI | 1 |
| Chipindo, HL | 1 |
| Volpato, AM | 1 |
| Budni, J | 1 |
| Steckert, AV | 1 |
| de Oliveira, MB | 1 |
| Heylmann, AS | 1 |
| da Rosa Silveira, F | 1 |
| Mastella, GA | 1 |
| Maravai, SG | 1 |
| Wessler, PG | 1 |
| Binatti, AR | 1 |
| Panizzutti, B | 1 |
| Schuck, PF | 1 |
| Quevedo, J | 1 |
| Gama, CS | 1 |
| Bokor, G | 1 |
| Anderson, PD | 1 |
| Zhao, T | 1 |
| Li, Y | 1 |
| Wei, W | 1 |
| Savage, S | 1 |
| Zhou, L | 1 |
| Ma, D | 1 |
| Tang, WK | 1 |
| Morgan, CJ | 2 |
| Lau, GC | 1 |
| Liang, HJ | 1 |
| Tang, A | 1 |
| Ungvari, GS | 1 |
| Rasmussen, KG | 1 |
| Arteche Andrés, MA | 1 |
| Zugasti Echarte, O | 1 |
| de Carlos Errea, J | 1 |
| Pérez Rodríguez, M | 1 |
| Leyún Pérez de Zabalza, R | 1 |
| Azcona Calahorra, MA | 1 |
| Andrade, C | 1 |
| Manji, H | 1 |
| Mullard, A | 1 |
| Amat, J | 1 |
| Dolzani, SD | 1 |
| Tilden, S | 1 |
| Christianson, JP | 1 |
| Kubala, KH | 1 |
| Bartholomay, K | 1 |
| Sperr, K | 1 |
| Ciancio, N | 1 |
| Watkins, LR | 1 |
| Maier, SF | 1 |
| Wu, R | 1 |
| Zhang, H | 1 |
| Xue, W | 1 |
| Zou, Z | 1 |
| Lu, C | 2 |
| Xia, B | 1 |
| Wang, W | 1 |
| Chen, G | 1 |
| da Silveira, VT | 1 |
| Medeiros, DC | 1 |
| Ropke, J | 1 |
| Guidine, PA | 1 |
| Rezende, GH | 1 |
| Moraes, MF | 1 |
| Mendes, EM | 1 |
| Macedo, D | 1 |
| Moreira, FA | 1 |
| de Oliveira, AC | 1 |
| Grande, LA | 1 |
| Liu, WL | 1 |
| Bian, SZ | 2 |
| Gu, ZL | 1 |
| Jiang, XG | 1 |
| Qin, ZH | 1 |
| Cortiñas, M | 1 |
| Oya, B | 1 |
| Caparros, P | 1 |
| Cano, G | 1 |
| Ibarra, M | 1 |
| Martínez, L | 1 |
| Le Cong, M | 1 |
| Gynther, B | 1 |
| Hunter, E | 1 |
| Schuller, P | 1 |
| Nagels, A | 1 |
| Kirner-Veselinovic, A | 1 |
| Wiese, R | 1 |
| Paulus, FM | 1 |
| Kircher, T | 1 |
| Krach, S | 1 |
| Zhang, Y | 1 |
| Zhang, J | 1 |
| Hu, L | 1 |
| Song, H | 1 |
| Li, J | 1 |
| Kang, L | 1 |
| Chan, WP | 1 |
| Chilvers, CR | 1 |
| Fredriksson, A | 1 |
| Archer, T | 1 |
| Cunningham, MO | 1 |
| Hunt, J | 1 |
| Middleton, S | 1 |
| LeBeau, FE | 1 |
| Gillies, MJ | 1 |
| Gillies, MG | 1 |
| Davies, CH | 1 |
| Maycox, PR | 1 |
| Whittington, MA | 1 |
| Racca, C | 1 |
| Howland, RH | 1 |
| Bleiberg, AH | 1 |
| Salvaggio, CA | 1 |
| Roy, LC | 1 |
| Kassutto, Z | 1 |
| Perry, EB | 1 |
| Cramer, JA | 1 |
| Cho, HS | 1 |
| Petrakis, IL | 1 |
| Karper, LP | 1 |
| Genovese, A | 1 |
| O'Donnell, E | 1 |
| Krystal, JH | 2 |
| D'Souza, DC | 1 |
| Yang, J | 1 |
| Muetzelfeldt, L | 1 |
| Kamboj, SK | 1 |
| Rees, H | 1 |
| Taylor, J | 1 |
| Smalla, KH | 1 |
| Mikhaylova, M | 1 |
| Sahin, J | 1 |
| Bernstein, HG | 1 |
| Bogerts, B | 1 |
| Schmitt, A | 1 |
| van der Schors, R | 1 |
| Smit, AB | 1 |
| Li, KW | 1 |
| Gundelfinger, ED | 1 |
| Kreutz, MR | 1 |
| Tamminga, CA | 1 |
| Conley, RR | 1 |
| Anand, A | 1 |
| Charney, DS | 1 |
| Oren, DA | 1 |
| Berman, RM | 1 |
| Hu, XS | 1 |
| Cappiello, A | 1 |
| Biersner, RJ | 1 |
| Harris, JA | 1 |
| Ryman, DH | 1 |
| Lilburn, JK | 1 |
| Dundee, JW | 1 |
| Nair, SG | 1 |
| Hausler, R | 1 |
| Cao, M | 1 |
| Magnin, C | 1 |
| Mulette, P | 1 |
| Ghoneim, MM | 1 |
| Hinrichs, JV | 1 |
| Mewaldt, SP | 1 |
| Petersen, RC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II, Randomised, Double-blind, Placebo- Controlled, Multi-site, Parallel Group Clinical Trial to Examine Ketamine as a Pharmacological Treatment for Alcohol Dependence in an Alcohol Dependent Population[NCT02649231] | Phase 2 | 96 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| Ketamine Versus Midazolam for Prehospital Agitation[NCT03554915] | 314 participants (Actual) | Observational | 2017-08-01 | Completed | |||
| ED Treatment of Suicidal Patients With Ketamine Infusion[NCT03502551] | Phase 2 | 0 participants (Actual) | Interventional | 2019-04-01 | Withdrawn (stopped due to Trial never received funding.) | ||
| Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression[NCT04234776] | Phase 4 | 88 participants (Anticipated) | Interventional | 2018-04-03 | Enrolling by invitation | ||
| Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department[NCT04260607] | Phase 3 | 2 participants (Actual) | Interventional | 2020-01-14 | Terminated (stopped due to As a busy MTF we were unable to retain a health care provider with the appropriate expertise to buy-in to this study once the initiating PI left military service.) | ||
| Effects of Low-dose S-ketamine on the Incidence of Postpartum Depression in Women With Prenatal Depression: a Randomized, Double-blind, Placebo-controlled Trial[NCT04414943] | 364 participants (Actual) | Interventional | 2020-06-19 | Completed | |||
| An Investigation of the Antidepressant Efficacy and Safety of an AMPAkine (Org 24448) in Major Depressive Disorder, A Double-Blind, Placebo-Controlled, Randomized Study[NCT00113022] | Phase 2 | 9 participants (Actual) | Interventional | 2005-05-31 | Terminated (stopped due to Terminated due to concerns about adverse events in separate study.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Time line follow back (NCT02649231)
Timeframe: 6 months
| Intervention | percentage of days abstinent (Mean) |
|---|---|
| Ketamine+Psychological Therapy | 86.4 |
| Ketamine+Education | 82.5 |
| Placebo+Psychological Therapy | 78.3 |
| Placebo+Education | 70.7 |
Time line follow back (NCT02649231)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketamine+Psychological Therapy | 13 |
| Ketamine+Education | 15 |
| Placebo+Psychological Therapy | 14 |
| Placebo+Education | 18 |
The MADRS is a measure of depression severity examined on a weekly basis. The minimum score on the 10 item scale is 0 indicating no depression. The maximum score is 60 indicating a very severe depression. Scores of 18 and above are generally considered to suggest significant levels of depression. (NCT00113022)
Timeframe: 8 weeks
| Intervention | Scores on a scale (Least Squares Mean) |
|---|---|
| Org 24448 | 26.425 |
| Placebo | 24.205 |
22 reviews available for ketamine and Behavior Disorders
| Article | Year |
|---|---|
Stress, mental disorder and ketamine as a novel, rapid acting treatment.
Topics: Antidepressive Agents; Humans; Hypothalamo-Hypophyseal System; Ketamine; Mental Disorders; Pituitary | 2022 |
Interventional Psychiatry and Neurotechnologies: Education and Ethics Training.
Topics: Curriculum; Humans; Ketamine; Mental Disorders; Psychiatry; Transcranial Magnetic Stimulation | 2023 |
Topics: Escitalopram; Hallucinogens; Humans; Ketamine; Mental Disorders; Psilocybin | 2023 |
Ketamine use in pediatric depression: A systematic review.
Topics: Adolescent; Adult; Child; Databases, Factual; Depression; Humans; Ketamine; Mental Disorders; Random | 2022 |
A systematic review of the incidence of medical serious adverse events in sub-anesthetic ketamine treatment of psychiatric disorders.
Topics: Adult; Anesthetics; Disease Progression; Humans; Incidence; Ketamine; Mental Disorders | 2024 |
The possible place for psychedelics in pharmacotherapy of mental disorders.
Topics: Antidepressive Agents; Hallucinogens; Humans; Ketamine; Mental Disorders; Psilocybin; Serotonin | 2023 |
Psychedelic drugs-a new era in
psychiatry?
.
Topics: Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Mental Disorders; N-Methyl-3,4-methylen | 2019 |
[Neurotrophic mechanisms of psychedelic therapy].
Topics: Animals; Hallucinogens; Humans; Ibogaine; Ketamine; Mental Disorders; Nerve Growth Factors; Psychiat | 2019 |
Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; | 2020 |
Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
Topics: Animals; Brain; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Mental Disorders; Menta | 2021 |
Blinding and expectancy confounds in psychedelic randomized controlled trials.
Topics: Confounding Factors, Epidemiologic; Hallucinogens; Humans; Ketamine; Lysergic Acid Diethylamide; Men | 2021 |
Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road.
Topics: Animals; Antidepressive Agents; Drug Development; Drug Discovery; Humans; Ketamine; Mental Disorders | 2021 |
Clinical Policy: Critical Issues in the Diagnosis and Management of the Adult Psychiatric Patient in the Emergency Department.
Topics: Acute Disease; Adult; Emergency Service, Hospital; Emergency Treatment; Evidence-Based Medicine; Exc | 2017 |
Effective Use of Animal Models for Therapeutic Development in Psychiatric and Substance Use Disorders.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Atomoxetine Hydrochloride; Attention D | 2018 |
Ketamine: an update on its abuse.
Topics: Gastrointestinal Diseases; Humans; Ketamine; Mental Disorders; Substance-Related Disorders; Urologic | 2014 |
Has psychiatry tamed the "ketamine tiger?" Considerations on its use for depression and anxiety.
Topics: Analgesics; Animals; Antidepressive Agents; Humans; Ketamine; Mental Disorders | 2016 |
Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression.
Topics: Administration, Intranasal; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Mental Disor | 2015 |
[Advances in research of ketamine addiction mechanism].
Topics: Anesthetics, Dissociative; Animals; Brain; Humans; Illicit Drugs; Ketamine; Mental Disorders; Rats; | 2009 |
Glutamate-modulating drugs & the treatment of mental disorders.
Topics: Acamprosate; Amantadine; Cycloserine; Glutamic Acid; Humans; Ketamine; Lamotrigine; Memantine; Menta | 2007 |
Psychiatric safety of ketamine in psychopharmacology research.
Topics: Adult; Aged; Clinical Trials as Topic; Dose-Response Relationship, Drug; Excitatory Amino Acid Antag | 2007 |
[A reviewing for abusing of ketamine].
Topics: Anesthetics, Dissociative; Cerebral Cortex; Humans; Illicit Drugs; Ketamine; Mental Disorders; Recep | 2007 |
The application of neuroimaging techniques to drug development.
Topics: Antipsychotic Agents; Brain; Brain Chemistry; Carbon Radioisotopes; Cerebrovascular Circulation; Deo | 1997 |
5 trials available for ketamine and Behavior Disorders
| Article | Year |
|---|---|
Comparative effects of (S)-ketamine and racemic (R/S)-ketamine on psychopathology, state of consciousness and neurocognitive performance in healthy volunteers.
Topics: Analgesics; Antidepressive Agents; Consciousness; Healthy Volunteers; Humans; Ketamine; Male; Mental | 2021 |
Effects of ketamine-induced psychopathological symptoms on continuous overt rhyme fluency.
Topics: Adult; Brain; Brain Mapping; Cognition Disorders; Double-Blind Method; Excitatory Amino Acid Antagon | 2012 |
Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.
Topics: Adult; Affect; Brief Psychiatric Rating Scale; Cognition Disorders; Double-Blind Method; Excitatory | 2000 |
Attenuation of psychic sequelae from ketamine [proceedings].
Topics: Humans; Ketamine; Mental Disorders; Preanesthetic Medication; Tranquilizing Agents | 1977 |
Ketamine: behavioral effects of subanesthetic doses.
Topics: Adolescent; Adult; Affect; Female; Headache; Humans; Ketamine; Learning; Male; Memory; Mental Disord | 1985 |
36 other studies available for ketamine and Behavior Disorders
| Article | Year |
|---|---|
Oral ketamine reduces the experience of stress in people with chronic suicidality.
Topics: Adult; Female; Humans; Ketamine; Mental Disorders; Self Report; Suicidal Ideation; Suicide | 2022 |
Psychedelics and ketamine are a symptom of psychiatry's woes, not a cure.
Topics: Hallucinogens; Humans; Ketamine; Mental Disorders; Psychiatry | 2023 |
Ketamine: A new chapter for clinical psychopharmacology?
Topics: Humans; Ketamine; Mental Disorders; Psychopharmacology | 2023 |
Ketamine-Assisted Psychodynamic Psychotherapy.
Topics: Female; Humans; Ketamine; Mental Disorders; Middle Aged; Psychotherapy; Psychotherapy, Psychodynamic | 2023 |
MANAGEMENT OF AMNESTIC AND BEHAVIORAL DISORDERS AFTER KETAMINE ANESTHESIA.
Topics: Amnesia; Anesthesia; Anesthesia, General; Animals; Dipeptides; Ketamine; Mental Disorders; Neuroprot | 2019 |
Ketamine in COVID-19 patients: Thinking out of the box.
Topics: COVID-19; COVID-19 Drug Treatment; Humans; Ketamine; Mental Disorders | 2021 |
Subanesthetic ketamine with an AMPAkine attenuates motor impulsivity in rats.
Topics: Animals; Antidepressive Agents; Cognition; Dose-Response Relationship, Drug; Glutamic Acid; Impulsiv | 2021 |
Commentary on: Comparative effects of (S)-ketamine and racemic (R/S)-ketamine on psychopathology, state of consciousness, and neurocognitive performance in healthy volunteers.
Topics: Consciousness; Healthy Volunteers; Humans; Ketamine; Mental Disorders; Psychopathology | 2021 |
Out of the night-time and into the day: Ketamine and MDMA as therapies for mental disorders.
Topics: Hallucinogens; Humans; Ketamine; Mental Disorders; Methamphetamine; N-Methyl-3,4-methylenedioxyamphe | 2021 |
Ketamine reduces the need for intubation in patients with acute severe mental illness and agitation requiring transport to definitive care: An observational study.
Topics: Adolescent; Adult; Cohort Studies; Emergency Medical Services; Female; Humans; Hypnotics and Sedativ | 2017 |
Synaptic phospholipids as a new target for cortical hyperexcitability and E/I balance in psychiatric disorders.
Topics: Animals; Astrocytes; Cells, Cultured; Central Nervous System Agents; Cerebral Cortex; Disease Models | 2018 |
Auditory Steady State Response; nature and utility as a translational science tool.
Topics: Acoustic Stimulation; Adult; Animals; Auditory Cortex; Brain; Disease Models, Animal; Electroencepha | 2019 |
Disruptive Psychopharmacology.
Topics: Consciousness; Humans; Ketamine; Mental Disorders; N-Methyl-3,4-methylenedioxyamphetamine; Psilocybi | 2019 |
Impact of a ketamine sedation protocol on intubation rates and undesirable outcomes in the transport of patients with acute behavioural disturbance.
Topics: Adult; Anesthetics, Dissociative; Emergency Medical Services; Female; Humans; Intubation, Intratrach | 2020 |
Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders.
Topics: Amphetamine; Cannabis; Drug Users; Ethanol; Female; Humans; Ketamine; Male; Mental Disorders; Pilot | 2013 |
The promise and perils of ketamine research.
Topics: Biomedical Research; Excitatory Amino Acid Antagonists; Humans; Ketamine; Mental Disorders; Psychoph | 2013 |
Omega-3 prevents behavior response and brain oxidative damage in the ketamine model of schizophrenia.
Topics: Animals; Brain; Brain Injuries; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Acid | 2014 |
Ketamine administered to pregnant rats in the second trimester causes long-lasting behavioral disorders in offspring.
Topics: Age Factors; Analgesics; Animals; Animals, Newborn; Body Temperature; Cell Proliferation; Disease Mo | 2014 |
Psychiatric morbidity in ketamine users attending counselling and youth outreach services.
Topics: Adolescent; Adult; Anxiety Disorders; Comorbidity; Counseling; Depressive Disorder; Excitatory Amino | 2015 |
[Anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma: Description of a case and anesthetic implications].
Topics: Adult; Anesthesia, Intravenous; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Consciousness Disor | 2015 |
Husseini Manji.
Topics: Antidepressive Agents; Clinical Trials, Phase III as Topic; Drug Industry; Humans; Ketamine; Male; M | 2015 |
Previous Ketamine Produces an Enduring Blockade of Neurochemical and Behavioral Effects of Uncontrollable Stress.
Topics: Anesthetics, Dissociative; Animals; Antidepressive Agents; Behavior, Animal; Chronic Disease; Ketami | 2016 |
Transgenerational impairment of hippocampal Akt-mTOR signaling and behavioral deficits in the offspring of mice that experience postpartum depression-like illness.
Topics: Age Factors; Animals; Depression, Postpartum; Disease Models, Animal; Eating; Excitatory Amino Acid | 2017 |
Effects of early or late prenatal immune activation in mice on behavioral and neuroanatomical abnormalities relevant to schizophrenia in the adulthood.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Brain; Disease Models, Animal; Embryo, | 2017 |
Sublingual Ketamine for Rapid Relief of Suicidal Ideation.
Topics: Administration, Sublingual; Adult; Humans; Ketamine; Male; Mental Disorders; Middle Aged; Psychotrop | 2017 |
[Oral ketamine-midazolam premedication of uncooperative patients in major outpatient surgery].
Topics: Adjuvants, Anesthesia; Administration, Oral; Ambulatory Surgical Procedures; Anesthetics, Dissociati | 2010 |
Ketamine sedation for patients with acute agitation and psychiatric illness requiring aeromedical retrieval.
Topics: Acute Disease; Adolescent; Adult; Air Ambulances; Anesthetics, Dissociative; Child; Female; Humans; | 2012 |
Gender differences in abusers of amphetamine-type stimulants and ketamine in southwestern China.
Topics: Adult; Age Factors; Amphetamine-Related Disorders; Anesthetics, Dissociative; Central Nervous System | 2013 |
Induction of anaesthesia in the home.
Topics: Adult; Aggression; Anesthesia; Anesthetics, Dissociative; Home Care Services, Hospital-Based; Humans | 2002 |
Neurobehavioural deficits associated with apoptotic neurodegeneration and vulnerability for ADHD.
Topics: Animals; Animals, Newborn; Apoptosis; Attention Deficit Disorder with Hyperactivity; Central Nervous | 2004 |
Region-specific reduction in entorhinal gamma oscillations and parvalbumin-immunoreactive neurons in animal models of psychiatric illness.
Topics: Animals; Disease Models, Animal; Entorhinal Cortex; Evoked Potentials; Excitatory Amino Acid Agonist | 2006 |
Low-dose ketamine: efficacy in pediatric sedation.
Topics: Adolescent; Atropine; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Evaluation; Dr | 2007 |
Journey through the K-hole: phenomenological aspects of ketamine use.
Topics: Adult; Attitude; Female; Health Status; Humans; Illicit Drugs; Ketamine; Male; Mental Disorders; Sub | 2008 |
A comparison of the synaptic proteome in human chronic schizophrenia and rat ketamine psychosis suggest that prohibitin is involved in the synaptic pathology of schizophrenia.
Topics: Adult; Analysis of Variance; Animals; Cells, Cultured; Cerebral Cortex; Disease Models, Animal; Elec | 2008 |
Emotional predisposition to psychotropic drug effects.
Topics: Adult; Affective Symptoms; Anesthesia, Intravenous; Female; Humans; Ketamine; Mental Disorders; Midd | 1977 |
Low frequency hearing threshold determination in newborns, infants and mentally retarded children by middle latency responses.
Topics: Acoustic Stimulation; Audiometry, Evoked Response; Audiometry, Pure-Tone; Auditory Threshold; Brain | 1991 |